Shots:

• The P-II study results involve assessing of REGN3500 + PBO- REGN3500 + Dupixent- Dupixent + PBO and PBO in 296 patients with moderate-to-severe asthma who were not well controlled on LABA and ICS therapy for 12wks.
• The P-II study resulted in meeting its 1EPs & 2EPs i.e- improvement in loss of asthma control & improvement in lung function respectively
• REGN3500 (SAR440340) is a mAb- inhibiting IL-33- being evaluated in P-II studies for asthma- chronic obstructive pulmonary disease and atopic dermatitis- invented utilizing Regeneron's VelocImmune technology- co-developed by Sanofi & Regeneron

Click here to read full press release/ article | Ref: Sanofi | Image: Stat